Literature DB >> 33209894

Diffusion tensor magnetic resonance imaging of white matter integrity in patients with HIV-associated neurocognitive disorders.

Tingting Zhao1, Jiehua Chen1, Hang Fang2, Danhui Fu1, Danke Su1, Wei Zhang2.   

Abstract

BACKGROUND: This study investigated the efficacy and neurotoxicity of highly active antiretroviral therapy (HAART) by evaluating white matter (WM) injury using diffusion tensor magnetic resonance imaging (DTI) in patients with human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND).
METHODS: Forty-six patients with HAND underwent DTI before and every six months during HAART treatment. DTI data, including fractional anisotropy (FA) and mean diffusivity (MD) values of structural WM before and after HAART, were compared. The relationship between DTI values and plasma viral loads was tested. MD was more sensitive than FA for evaluating WM injury in HAND-positive patients.
RESULTS: Following 12 months of HAART, increased MD values (compared to 6 months of HAART) were observed in the right temporal lobe, right parietal lobe, right occipital lobe, right anterior limb of the internal capsule, right lenticular nucleus, the right cerebral peduncle, left caudate nucleus, left dorsal thalamus, and left posterior limb of the internal capsule. MD values in the left genu of the internal capsule (r=0.350, P=0.017) and left corona radiata (r=0.338, P=0.021) were positively correlated with plasma viral loads.
CONCLUSIONS: DTI may be useful for assessing the efficacy and neurotoxicity of HAART in HAND-positive patients. Starting HAART may halt WM injury; however, prolonged HAART could worsen WM injury, highlighting the importance of optimal HAART duration. 2020 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Human immunodeficiency virus (HIV); diffusion tensor imaging; highly active antiretroviral therapy (HAART); white matter (WM)

Year:  2020        PMID: 33209894      PMCID: PMC7661883          DOI: 10.21037/atm-20-6342

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


Introduction

The incidence of human immunodeficiency virus (HIV) infection shows regional variations (1). Guangxi has the second-highest prevalence of patients with HIV and mortality because of HIV infection in China (2). The data from the China Centers for Disease Control Epidemic Information System reported that Guangxi had 85,576 cases of HIV infection and AIDS and 49,109 cases of death following HIV infection in December 2018. HIV penetrates the central nervous system (CNS) at the early stages of infection, even in the pre-acquired immune deficiency syndrome phase (3), and leads to inflammation in the brain. Ongoing CNS inflammation may lead to cognitive and behavioral abnormalities, which are called HIV-associated neurocognitive disorders (HAND) (4). Advancements in highly active antiretroviral therapy (HAART) has led to a profound decrease in the morbidity and mortality of HIV-infected individuals (5,6). However, patients with HIV continue to experience HAND (7,8). This cognitive dysfunction can affect daily function (9) and increase the risk of death in patients with HIV (10). Although research has suggested HAART cannot reverse previous damage, recent studies have reported that effective HAART could prevent the progression of CNS injury (11,12). However, it is possible that the prolonged use of HAART may also induce neurotoxicity (13,14). It is often challenging to diagnose HAND and post-HAART neurocognitive functions with a neuropsychological (NP) battery of tests because of differences in language and cultural environments (2,15). Also, NP tests are tedious and cannot be performed by patients with physical disabilities (16). Diffusion tensor imaging (DTI) is an imaging modality that can be used for the quantitative assessment of brain white matter (WM) abnormalities associated with the initial stages of HIV (17-19). DTI tests the directional nature of water diffusion through cellular structures in the brain WM and shows brain integrity with fractional anisotropy (FA) and mean diffusivity (MD) (20-22). FA and MD can supply complementary quantitative information on WM structure; FA reflects axonal microstructural integrity, and MD reflects the average diffusion in tissue (23). Although some results have been controversial (24), most studies have shown that FA was decreased, and MD was increased in different WM regions of HIV-infected patients (17-22). Stubbe-Drger et al. (25) found that there were no statistical differences in FA between patients taking HAART and those who not. Patients with HAND had significant FA reduction relative to patients without HAND. However, the primary focus of the earlier DTI studies of HAND has been the differences in WM structure between HIV-infected individuals and non-infected controls. To our knowledge, the causative relationship between the neurotoxicity of HAART and neurocognitive function impairment in patients with HAND individuals is still uncertain. Therefore, it is essential to investigate the WM integrity of patients with HAND by assessing differences in DTI values and plasma viral load following 6 and 12 months of HAART. The purpose of this study was to test the efficacy and neurotoxicity of HAART in HIV-infected individuals using DTI. The NP battery of tests was assessed as secondary endpoints. We present the following article in accordance with the MDAR reporting checklist (available at http://dx.doi.org/10.21037/atm-20-6342).

Methods

Patients

We randomly selected 48 patients (31 men and 17 women; mean age, 43.96±13.21 years) with HAND who underwent magnetic resonance imaging (MRI) at the Affiliated Tumor Hospital of Guangxi Medical University and received HAART at the Fourth People’s Hospital of Nanning from January 2017 to January 2018. The follow-up period was up to 12 months of HAART. Two neurologists/psychiatrists confirmed HAND with 5 years of relevant clinical experience with AIDS-related nervous system symptoms. The symptoms were assessed according to the diagnostic criteria set up by the American Academy of Neurology (Grant 2008) to support a uniform standard throughout the diagnostic process. Following these criteria (2,9,15), patients with comorbid conditions that could affect cognitive or daily functioning were excluded from the study. The values of plasma viral loads were with the normal ranges used at our institution. All procedures performed in this study involving human participants were in accordance with the Declaration of Helsinki (as revised in 2013). This study was approved by the Ethics Committee of Wuming Hospital of Guangxi Medical University (No. FSWM2020-126). All patients signed informed consent forms.

Image acquisition

All DTI scans of the brain were acquired using a 1.5-T scanner (Avanto, Siemens, Erlangen, Germany) with an 8-channel phased-array head coil and equipped with the following parameters: axial T1-weighted sequence [repetition time (TR) =199 ms, echo time (TE) =4.76 ms], axial T2-weighted sequence (TR =4,000 ms, TE =105 ms), axial fluid attenuation inversion recovery (TR =7,600 ms, TE =92 ms), field of view (FOV) =210 mm, matrix =384×192, section thickness =6 mm, intersection gaP =2 mm, and flip angle =70°. A transverse diffusion tensor single-shot echo-planar scan was performed with bipolar diffusion gradients applied along 20 non-collinear and non-coplanar directions (b0 =0 and b1 =1,000 s/mm2) using the following parameters: TR =5,000 ms, TE =97 ms; FOV =210 mm; matrix =128×128, flip angle =90°, total acquisition 35 slices with 4 mm thickness, and 1 gap.

DTI analysis

All DTI data were processed with the functional MRI of the brain software library of Siemens Company’s ADW42 workstation. All images were processed using motion correction to stop the misregistration caused by slight movements during scanning. Gaussian smoothing was applied to remove the background noise without the loss of valuable information. The software generated three-dimensional color DTI, FA, and MD maps. We identified 30 primary regions of interest (ROIs) of WM tracts to investigate the WM characteristics of the whole brain before and after HAART, including the WM of the frontal lobe, temporal lobe, parietal lobe, occipital lobe, dorsal thalamus, anterior limb of the internal capsule, posterior limb of the internal capsule, genu of the internal capsule, genu of the corpus callosum, the body of the corpus callosum, splenium of the corpus callosum, corona radiata, lenticular nucleus, caudate nucleus, cerebral peduncles, and middle cerebellar peduncle. ROIs were manually drawn to extract 6–9-mm2 circles while excluding areas of grey matter or cerebrospinal fluid (CSF). The area of the ROI selected was less than the area of the corresponding brain WM structure (). ROIs were repeatedly measured three times, and the mean FA and MD in each WM tract were calculated for each patient.
Figure 1

Region of interests of a healthy person (A) and patients with human immunodeficiency virus-associated neurocognitive disorders (B).

Region of interests of a healthy person (A) and patients with human immunodeficiency virus-associated neurocognitive disorders (B).

NP tests

The 14 NP tests are described in our earlier studies (2).

Statistical analysis

Statistical analyses were performed using SPSS version 22.0 (IBM Corp., Armonk, NY, USA) statistical software. These results were expressed as mean ± standard deviation. To investigate changes in WM injury before and after HAART, we conducted repeated measures, univariate analysis of variance, and multiple comparisons, using Bonferroni correction, which was performed in the three groups. Bivariate correlation analyses were used to determine the correlation between plasma viral loads and both DTI values and NP test results. For all analyses, P<0.05 was considered statistically significant.

Results

Patient characteristics

Forty-six patients (29 men and 17 women) with HAND completed the follow-up period, with a loss to the follow-up rate of 4.2%. Of the 46 patients, 14 patients had received senior high school education or above, 32 were married, and 37 had no history of drug abuse. Demographic characteristics are shown in .
Table 1

Demographic characteristics of study participants

Demographic characteristicsN (constituent ratio %)
Sex
    Male29 (63.04)
    Female17 (36.96)
Age (in years)
    20–299 (19.56)
    30–395 (10.87)
    40–4915 (32.61)
    50–5912 (26.09)
    60–655 (10.87)
Ethnicity
    Han19 (41.30)
    Zhuang25 (54.35)
    Yao2 (4.35)
Education
    Primary school or less12 (26.09)
    Junior high school or less20 (43.48)
    High school or higher14 (30.43)
Marital status
    Married32 (69.56)
    Unmarried10 (21.74)
    Divorced2 (4.35)
    Widowed2 (4.35)
Profession
    Farmer17 (39.95)
    Staff10 (21.74)
    Migrant laborer10 (21.74)
    Health personnel2 (4.35)
    Unemployed5 (10.87)
    Other2 (4.35)
History of drug abuse
    None 37 (80.44)
    Ever9 (19.56)

The FA values of WM tracts before and after HAART

We observed changes in the FA values of WM tracts after HAART in the follow-up period (, ). HAND-positive patients exhibited significantly higher FA values in the right temporal lobe and right lenticular nucleus and lowered FA in the right caudate nucleus and right dorsal thalamus after six months of HAART than FA values before HAART. Further, FA values are higher in the right caudate nucleus and lower in the right lenticular nucleus and right dorsal thalamus after 12 months of HAART than after 6 months of therapy (P<0.05).
Table 2

The FA values of 46 study participants before and after HAART

RegionGroupFA95% CIFPa
Frontal lobe_R10.445±0.0330.436–0.4550.3840.682
20.451±0.0360.440–0.461
30.450±0.0320.441–0.460
Frontal lobe_L10.438±0.0290.430–0.4471.7020.188
20.430±0.0210.423–0.436
30.438±0.0280.429–0.446
Temporal lobe_R10.396±0.0290.388–0.40513.3220.000
20.426±0.0370.415–0.437*
30.434±0.0410.422–0.447*
Temporal lobe_L10.452±0.0370.440–0.4630.4320.607
20.447±0.0500.432–0.462
30.445±0.0110.441–0.448
Parietal lobe_R10.527±0.0290.518–0.5354.5590.013
20.536±0.0300.527–0.545
30.545±0.0310.536–0.554
Parietal lobe_L10.530±0.0220.524–0.5370.0880.817
20.531±0.0160.526–0.536
30.534±0.0730.512–0.556
Occipital lobe_R10.218±0.0360.208–0.2291.9320.160
20.207±0.0370.196–0.218
30.218±0.0270.210–0.226
Occipital lobe_L10.206±0.0190.200–0.2112.5460.084
20.202±0.0240.195–0.209
30.211±0.0170.206–0.216
Genu of the corpus callosum10.800±0.0340.790–0.8100.7020.498
20.799±0.0350.789–0.810
30.792±0.0340.782–0.802
Splenium of the corpus callosum10.856±0.0940.828–0.8841.5300.224
20.841±0.0840.816–0.866
30.867±0.0160.862–0.872
Body of the corpus callosum_R10.809±0.0400.797–0.8212.0880.130
20.794±0.0380.783–0.805
30.807±0.0400.795–0.819
Body of the corpus callosum_L10.818±0.3750.706–0.9290.1970.822
20.775±0.3000.686–0.864
30.809±0.3470.706–0.913
Anterior limb of the internal capsule_R10.614±0.0350.604–0.6251.5100.226
20.612±0.0460.598–0.626
30.626±0.0410.614–0.638
Anterior limb of the internal capsule_L10.615±0.0890.588–0.6410.8830.369
20.619±0.0100.616–0.622
30.630±0.0380.619–0.642
Posterior limb of the internal capsule_R10.712±0.0290.703–0.7211.2990.278
20.701±0.0350.690–0.711
30.707±0.0360.697–0.718
Posterior limb of the internal capsule_L10.724±0.0240.717–0.7310.0310.970
20.725±0.0270.717–0.733
30.725±0.0210.719–0.731
Genu of the internal capsule_R10.653±0.0440.640–0.6660.7080.495
20.641±0.0420.629–0.654
30.645±0.0440.632–0.658
Genu of the internal capsule_L10.656±0.0390.644–0.6670.3650.695
20.649±0.0410.637–0.662
30.650±0.0400.638–0.662
Lenticular nucleus_R10.233±0.0260.225–0.24126.2540.000
20.269±0.0200.263–0.275*
30.243±0.0240.236–0.250#
Lenticular nucleus_L10.242±0.1140.208–0.2760.0190.964
20.245±0.0290.237–0.254
30.245±0.0990.216–0.275
Caudate nucleus_R10.190±0.0490.176–0.2055.0170.017
20.170±0.0220.163––0.176*
30.186±0.0170.181–0.191#
Caudate nucleus_L10.201±0.0240.194–0.2087.1130.001
20.189±0.0220.183–0.196
30.183±0.0200.178–0.189*
Dorsal thalamus_R10.300±0.0150.295–0.3059.3010.000
20.304±0.0140.300–0.308
30.291±0.0190.285–0.296*#
Dorsal thalamus_L10.298±0.0140.293–0.3024.4260.020
20.289±0.0090.287–0.292*
30.290±0.0190.285–0.296
Corona radiata_R10.414±0.0240.407–0.4211.0280.362
20.419±0.0180.414–0.424
30.420±0.0210.413–0.426
Corona radiata_L10.431±0.0710.410–0.4520.0820.899
20.429±0.0540.413–0.445
30.427±0.0220.420–0.433
Cerebral pedunculus_R10.553±0.0320.543–0.5622.3100.105
20.538±0.0360.527–0.549
30.548±0.0360.538–0.559
Cerebral pedunculus_L10.538±0.0170.532–0.5431.9010.174
20.558±0.0870.532–0.583
30.542±0.0080.539–0.544
Middle cerebellar peduncle_R10.713±0.0320.704–0.7230.5030.568
20.663±0.2850.578–0.747
30.707±0.3630.599–0.815
Middle cerebellar peduncle_L10.724±0.0450.711–0.7382.5800.081
20.705±0.0360.695–0.716
30.717±0.0460.703–0.731

Data are mean values ± standard deviation. Pa values for comparison among three groups (before HAART, after 6 months of HAART, and after 12 months of HAART). *, P<0.05 (compared with before HAART); #, P<0.05 (compared with 6 months of HAART). Group 1, without HAART; Group 2, after six months of HAART; Group 3, after 12 months of HAART. CI, confidence interval; FA, fractional anisotropy; HAART, highly active antiretroviral therapy; L, left; R, right.

Figure 2

The FA values of WM tracts before and after HAART. *, P<0.05. HAART, highly active antiretroviral therapy; AIC, anterior limb of the internal capsule; BCC, the body of the corpus callosum; CN, caudate nucleus; CP, cerebral peduncle; CR, corona radiata; DT, dorsal thalamus; FA, fractional anisotropy; FL, frontal lobe; GCC, genu of the corpus callosum; GIC, genu of the internal capsule; HAART, highly active antiretroviral therapy; L, left; LN, lenticular nucleus; MCP, middle cerebellar peduncle; OL, occipital lobe; PIC, posterior limb of the internal capsule; PL, parietal lobe; R, right; SCC, splenium of the corpus callosum; TL, temporal lobe WM, white matter.

Data are mean values ± standard deviation. Pa values for comparison among three groups (before HAART, after 6 months of HAART, and after 12 months of HAART). *, P<0.05 (compared with before HAART); #, P<0.05 (compared with 6 months of HAART). Group 1, without HAART; Group 2, after six months of HAART; Group 3, after 12 months of HAART. CI, confidence interval; FA, fractional anisotropy; HAART, highly active antiretroviral therapy; L, left; R, right. The FA values of WM tracts before and after HAART. *, P<0.05. HAART, highly active antiretroviral therapy; AIC, anterior limb of the internal capsule; BCC, the body of the corpus callosum; CN, caudate nucleus; CP, cerebral peduncle; CR, corona radiata; DT, dorsal thalamus; FA, fractional anisotropy; FL, frontal lobe; GCC, genu of the corpus callosum; GIC, genu of the internal capsule; HAART, highly active antiretroviral therapy; L, left; LN, lenticular nucleus; MCP, middle cerebellar peduncle; OL, occipital lobe; PIC, posterior limb of the internal capsule; PL, parietal lobe; R, right; SCC, splenium of the corpus callosum; TL, temporal lobe WM, white matter.

The MD values of WM tracts before and after HAART

We also observed changes in the MD values of WM tracts after HAART in the follow-up period (, ). HAND-positive patients exhibited significantly lower MD in the right temporal lobe, right parietal lobe, right lenticular nucleus, the right cerebral peduncle, left caudate nucleus, left dorsal thalamus, and genu of the corpus callosum and higher MD in the right dorsal thalamus after 6 months of HAART than before HAART. HAND-positive patients exhibited significantly higher MD in the right temporal lobe, right occipital lobe, right anterior limb of the internal capsule, right dorsal thalamus, and lower MD in the left genu of the internal capsule after 12 months of HAART than before HAART. MD values were higher in the right temporal lobe, right parietal lobe, right occipital lobe, right anterior limb of the internal capsule, right lenticular nucleus, the right cerebral peduncle, left caudate nucleus, left dorsal thalamus, and left posterior limb of the internal capsule and lower in the left lenticular nucleus after 12 months of HAART than after 6 months of therapy (P<0.05).
Table 3

The MD values of 46 study participants before and after HAART

RegionGroupMD95% CIFPa
Frontal lobe_R10.754±0.0470.740–0.7681.4070.250
20.741±0.0300.732–0.750
30.753±0.0410.741–0.765
Frontal lobe_L10.753±0.0420.741–0.7650.0480.954
20.754±0.0410.741–0.766
30.751±0.0400.739–0.763
Temporal lobe_R10.798±0.0250.790–0.80511.9080.000
20.781±0.0340.771–0.791*
30.818±0.0480.804–0.832*#
Temporal lobe_L10.776±0.0280.767–0.7842.3480.131
20.742±0.0420.730–0.755
30.802±0.2220.736–0.868
Parietal lobe_R10.794±0.0120.791–0.79810.2970.001
20.767±0.0350.757–0.778*
30.814±0.0750.791–0.836#
Parietal lobe_L10.779±0.0600.761–0.7971.1900.298
20.765±0.0190.760–0.771
30.775±0.0340.765–0.785
Occipital lobe_R10.774±0.0400.762–0.78617.2150.000
20.757±0.0390.746–0.769
30.800±0.0250.793–0.808*#
Occipital lobe_L10.787±0.0260.780–0.7950.2860.720
20.788±0.0280.779–0.796
30.792±0.0390.780–0.803
Genu of the corpus callosum10.793±0.0300.784–0.8028.4370.000
20.761±0.0500.746–0.776*
30.779±0.0350.769–0.789
Splenium of the corpus callosum10.749±0.0470.735–0.7630.7550.473
20.741±0.0410.729–0.753
30.752±0.0410.740–0.765
Body of the corpus callosum_R10.847±0.0620.829–0.8661.5570.216
20.828±0.0510.813–0.844
30.844±0.0510.829–0.859
Body of the corpus callosum_L10.846±0.0410.834–0.8583.0310.053
20.834±0.0320.824–0.843
30.829±0.0360.818–0.839
Anterior limb of the internal capsule_R10.761±0.0380.750–0.7725.8980.007
20.769±0.0280.760–0.777
30.781±0.0110.778–0.784*#
Anterior limb of the internal capsule_L10.770±0.0310.761–0.7790.1070.899
20.769±0.0280.760–0.777
30.767±0.0310.758–0.776
Posterior limb of the internal capsule_R10.740±0.0220.734–0.7472.7160.081
20.727±0.0260.719–0.735
30.740±0.0400.728–0.751
Posterior limb of the internal capsule_L10.726±0.0400.714–0.7387.1360.001
20.712±0.0340.701–0.722
30.739±0.0210.733–0.745#
Genu of the internal capsule_R10.759±0.0160.755–0.7642.4050.106
20.736±0.0730.714–0.757
30.758±0.0630.739–0.776
Genu of the internal capsule_L10.761±0.0390.749–0.7723.3410.040
20.748±0.0410.736–0.760
30.739±0.0410.727–0.752*
Lenticular nucleus_R10.781±0.0400.769–0.7937.1590.002
20.759 ±0.0330.749–0.769*
30.783±0.0210.777–0.789#
Lenticular nucleus_L10.752±0.0510.737–0.7673.9180.023
20.777±0.0520.761–0.792
30.751±0.0470.738–0.765#
Caudate nucleus_R10.758±0.0390.746–0.7701.5790.212
20.751±0.0360.740–0.761
30.763±0.0200.757–0.769
Caudate nucleus_L10.773±0.0400.761–0.7856.7290.005
20.742±0.0230.735–0.749*
30.766±0.0560.750–0.783#
Dorsal thalamus_R10.717±0.0400.705–0.72963.4180.000
20.804±0.0520.789–0.819*
30.791±0.0320.781–0.800*
Dorsal thalamus_L10.770±0.0200.764–0.77614.7680.000
20.734±0.0330.724–0.743*
30.762±0.0440.749–0.776#
Corona radiata_R10.769±0.0170.764–0.7741.6550.197
20.752±0.0730.730–0.774
30.750±0.0590.733–0.767
Corona radiata_L10.758±0.0300.749–0.7671.2950.279
20.745±0.0370.734–0.756
30.752±0.0410.740–0.764
Cerebral pedunculus_R10.790±0.0270.782–0.79814.5330.000
20.764±0.0350.754–0.775*
30.810±0.0600.792–0.828#
Cerebral pedunculus_L10.791±0.0410.779–0.8041.9960.142
20.805±0.0330.795–0.815
30.797±0.0330.787–0.807
Middle cerebellar peduncle_R10.697±0.0670.677–0.7171.2710.279
20.697±0.0310.688–0.706
30.710±0.0210.704–0.717
Middle cerebellar peduncle_L10.696±0.0530.680–0.7120.7760.464
20.704±0.0480.690–0.718
30.707±0.0350.697–0.718

Data are mean values ± standard deviation. Pa values for comparison among three groups (before HAART, after 6 months of HAART, and after 12 months of HAART). *, P<0.05 (compared with before HAART); #, P<0.05 (compared with 6 months of HAART); Group 1, without HAART; Group 2, 6 months of HAART; and Group 3, 12 months of HAART. CI, confidence interval; HAART, highly active antiretroviral therapy; MD, mean diffusivity; L, left, R, right.

Figure 3

The MD values of WM tracts before and after HAART. *, P<0.05. HAART, highly active antiretroviral therapy; AIC, anterior limb of the internal capsule; BCC, the body of the corpus callosum; CN, caudate nucleus; CP, cerebral peduncle; CR, corona radiata; DT, dorsal thalamus; FL, frontal lobe; GCC, genu of the corpus callosum; GIC, genu of the internal capsule; HAART, highly active antiretroviral therapy; L, left; LN, lenticular nucleus; MCP, middle cerebellar peduncle; MD, mean diffusivity; OL, occipital lobe; PIC, posterior limb of the internal capsule; PL, parietal lobe; R, right; SCC, splenium of the corpus callosum; TL, temporal lobe WM, white matter.

Data are mean values ± standard deviation. Pa values for comparison among three groups (before HAART, after 6 months of HAART, and after 12 months of HAART). *, P<0.05 (compared with before HAART); #, P<0.05 (compared with 6 months of HAART); Group 1, without HAART; Group 2, 6 months of HAART; and Group 3, 12 months of HAART. CI, confidence interval; HAART, highly active antiretroviral therapy; MD, mean diffusivity; L, left, R, right. The MD values of WM tracts before and after HAART. *, P<0.05. HAART, highly active antiretroviral therapy; AIC, anterior limb of the internal capsule; BCC, the body of the corpus callosum; CN, caudate nucleus; CP, cerebral peduncle; CR, corona radiata; DT, dorsal thalamus; FL, frontal lobe; GCC, genu of the corpus callosum; GIC, genu of the internal capsule; HAART, highly active antiretroviral therapy; L, left; LN, lenticular nucleus; MCP, middle cerebellar peduncle; MD, mean diffusivity; OL, occipital lobe; PIC, posterior limb of the internal capsule; PL, parietal lobe; R, right; SCC, splenium of the corpus callosum; TL, temporal lobe WM, white matter.

Correlations between DTI metrics and plasma viral loads before and after HAART

There was a strong negative correlation between plasma loads and HAART in HIV-infected patients (P<0.05). Specifically, as the treatment progressed, the plasma loads decreased (). There was a significant difference in plasma viral loads before and after six months of HAART (before, 3.696±0.707 copies/mL. Also, after six months, the levels were 2.159±0.444 copies/mL, P<0.001). Further, the plasma viral loads were significantly lower after 12 months of HAART (1.430±0.337 copies/mL) than before HAART (P<0.001) and after 6 months of HAART (P<0.001). The FA values of the main WM tracts were not statistically correlated with plasma viral loads; however, the MD values in the left genu of the internal capsule (r=0.350, P=0.017) and left corona radiata (r=0.338, P=0.021) were positively correlated with plasma viral loads before HAART and after 12 months of HAART.
Figure 4

The plasma viral loads before and after HAART. HAART, highly active antiretroviral therapy.

The plasma viral loads before and after HAART. HAART, highly active antiretroviral therapy.

Analytical comparison of NP test results before and after HAART

The NP test scores of HAND-positive patients showed significantly better in all the testing methods except for the Wisconsin Card Sorting Test classification after 6 months of HAART than before HAART. The scores were worse in wood puzzles, immediate visual memory, delayed visual memory, Stroop C, Stroop CW, non-vocabulary fluency, and concept fluency test after 12 months of HAART than after six months of therapy (P<0.05) (). The digit span test value was positively correlated with plasma viral loads before HAART and after 12 months of HAART (r=0.352, P=0.016).
Table 4

The neuropsychological tests of 46 study participants before and after HAART

Testing methodGroupScores95% CIFPa
Digit symbol test147.91±6.5645.96–49.868.9490.000
252.57±6.9550.50–54.63*
350.96±6.0849.15–52.76*
Trail making test178.63±16.0073.88–83.381.9310.165
273.09±15.7768.41–77.77*
372.89±18.1067.52–78.27
Arithmetic score17.83±1.107.50–8.1531.8030.000
210.94±2.4010.22–11.65*
310.20±2.339.50–10.89*
Digit span test110.30±2.569.54–11.079.8470.000
212.48±1.5212.03–12.93*
311.96±3.1811.01–12.90*
Wood puzzle118.61±1.9718.02–19.19103.8490.000
228.35±2.8527.50–29.19*
321.96±4.4720.63–23.26*#
Immediate visual memory19.39±1.209.04–9.7564.0320.000
212.59±1.3412.19–12.99*
311.35±1.3510.95–11.75*#
Visual delayed memory16.17±1.005.88–6.47134.3820.000
210.96±1.1910.60–11.31*
38.00±1.847.45–8.55*#
Stroop C188.91±16.8983.90–93.938.1750.001
277.96±18.0872.59–83.33*
386.80±18.3881.35–92.26#
Stroop CW1106.59±19.66100.75–112.4315.1750.000
292.54±19.4086.78–98.30*
3100.00±17.9094.68–105.32#
Vocabulary fluency18.98±0.988.69–9.27121.3470.000
216.76±2.0916.14–17.38*
311.65±3.3710.65–12.65*#
Non-vocabulary fluency19.44±0.899.17–9.70138.6290.000
217.65±1.9317.08–18.23*
312.07±3.4211.05–13.08*#
Concept fluency test19.57±0.989.27–9.8661.5890.000
216.02±3.6614.94–17.11*
312.13±3.2011.18–13.08*#
WSCT persistent error12.24±1.841.69–2.7948.7460.000
20.20±0.400.08–0.32*
30.26±0.490.12–0.41*
WCST classification15.39±1.145.05–5.7314.0820.000
24.52±1.034.22–4.83*
34.57±0.934.29–4.84*

Data are mean values ± standard deviation. Pa values for comparison among three groups (before HAART, after 6 months of HAART, and after 12 months of HAART). *, P<0.05 (compared with before HAART); #, P<0.05 (compared with 6 months of HAART). Group 1, without HAART, Group 2, 6 months of HAART, and Group 3, 12 months of HAART. CI, confidence interval; HAART, highly active antiretroviral therapy; WCST, Wisconsin Card Sorting Test.

Data are mean values ± standard deviation. Pa values for comparison among three groups (before HAART, after 6 months of HAART, and after 12 months of HAART). *, P<0.05 (compared with before HAART); #, P<0.05 (compared with 6 months of HAART). Group 1, without HAART, Group 2, 6 months of HAART, and Group 3, 12 months of HAART. CI, confidence interval; HAART, highly active antiretroviral therapy; WCST, Wisconsin Card Sorting Test.

Discussion

The current study investigated the efficacy and neurotoxicity of HAART by evaluating the extent of brain WM injury using DTI in patients with HAND. Results from this study showed that changes in MD in WM tracts were more extensive than changes in FA in WM tracts. Unlike the FA values, the MD values were statistically correlated with plasma viral loads. Like earlier studies, our results showed that changes in the MD values were more commonly observed than changes in the FA values (17,19,20). DTI measures four parameters, including FA, axial diffusivity (AD), MD, and radial diffusivity (RD). In this study, we focused only on FA and MD, while AD and RD were not calculated. However, FA and MD are influenced by AD and RD. FA can reflect the microstructural integrity of axons through the deviation of water motion (23), and studies have suggested that changes in RD may induce FA abnormalities (20,23,26). RD is known to be related to the destruction of myelin integrity and is a marker for demyelination induced by inflammation (27-30). MD may reflect cell degeneration and membrane density, though the speed of water molecule diffusion (31,32). MD abnormalities have been attributed primarily to AD changes (20), and increased AD is a marker of chronic axonal damage (31,32). Our results showed that MD was more sensitive than FA in evaluating WM injury in HAND-positive patients. These findings showed that axonal injury might exist before the integrity of myelin is disrupted. However, it is unclear if axonal damage can trigger demyelination. Therefore, the relationship between axonal and myelin damage should be determined in future HAND pathology studies. The detrimental effects on WM structure and function following the prolonged use of HAART are still controversial (33-36). Therefore, our study tested the correlation between DTI metrics and HAART, which ultimately reflects the changes in the WM microstructure. Our results supply evidence HAART may prevent the progression of WM injury, at least in the short run. The early implementation of HAART in HIV-infected patients helps suppress viral replication in the plasma and CSF (8). However, the changes in the DTI parameters of the right caudate nucleus and right dorsal thalamus observed in our study are difficult to explain. These findings might be explained by the ability of HIV to penetrate the blood-CSF barrier and accumulate in the CSF (3). Drugs must first cross the blood-brain barrier (BBB) to enter the CNS, and an intact BBB causes this entry to be challenging. These results may also be because of differences in the cognitive status and disease duration of different WM areas in patients with HAND. Our findings suggest that HAART may prevent the progression of CNS injury, which emphasizes the importance of prompt treatment in infected individuals. As secondary endpoints, the results of NP tests also confirm this view, HAART improves the WM, at least in the short run. The MD values in the left genu of the internal capsule and left corona radiata are positively correlated with plasma viral loads, which might be because of the selective involvement of WM in patients with HAND. Specifically, the virus penetrates vulnerable regions of the BBB to infect and activate local CNS immune cells. Studies have shown that periventricular WM, especially corona radiata, are more vulnerable to viral invasion and neuroinflammation in HIV-infected individuals (18,31,37-39). Higher plasma viral loads have been associated with higher MD values in the left genu of the internal capsule and left corona radiata and increased activity and replication of HIV, which may lead to viral accumulation in the CSF. Therefore, we used DTI as a measurement of neuronal injury to monitor CSF viral loads. However, further investigation must characterize the relationship between DTI values and CSF viral loads. After 12 months of HAART, the MD values in the right temporal lobe, right parietal lobe, right occipital lobe, right anterior limb of the internal capsule, right lenticular nucleus, right cerebral peduncle, left caudate nucleus, left dorsal thalamus, and left posterior limb of the internal capsule, which is significantly higher than the MD values after six months of HAART. The scores were worse for the wood puzzle, immediate visual memory, delayed visual memory, Stroop C, Stroop CW, non-vocabulary fluency, and the concept fluency test after 12 months of HAART than after six months of therapy. These results prove that damage to the WM of these brain regions progressed in virologically well-controlled patients with HAND after HAART. It is neurotoxicity damage to the nerve from HAART that can lead to changes in DTI parameters. Therefore, we hypothesize that the side effects of HAART caused these results. However, further studies are needed to resolve this issue. Limitations in this study included a small size sample and short follow-up duration. However, our DTI findings after six months of HAART were like earlier reports, which support the reliability of these results. Further, we focused only on FA and MD in the current study; AD and RD were omitted. However, studies have reported that changes induce FA changes primarily in RD (20,23,26) and MD changes are mainly attributed to AD alterations (20). Therefore, we believe our results suffice to prove injury to the WM. Data on the lifestyle of participants is not collected, and different lifestyle factors, including alcohol use, may contribute to post-HAART results. In conclusion, our findings show that DTI may be an impersonal imaging modality for assessing the efficacy and neurotoxicity of HAART in HAND-positive patients. Starting HAART may halt the structural deterioration of the WM; however, prolonged HAART could worsen the WM injury, emphasizing the importance of optimal HAART duration. DTI and NP tests may be used as markers for real-time dynamic monitoring efficacy and neurotoxicity of HAART, and this may optimize treatment strategies for HAND-positive patients. The article’s supplementary files as
  39 in total

1.  Updated research nosology for HIV-associated neurocognitive disorders.

Authors:  A Antinori; G Arendt; J T Becker; B J Brew; D A Byrd; M Cherner; D B Clifford; P Cinque; L G Epstein; K Goodkin; M Gisslen; I Grant; R K Heaton; J Joseph; K Marder; C M Marra; J C McArthur; M Nunn; R W Price; L Pulliam; K R Robertson; N Sacktor; V Valcour; V E Wojna
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

2.  Identifying the white matter impairments among ART-naïve HIV patients: a multivariate pattern analysis of DTI data.

Authors:  Zhenchao Tang; Zhenyu Liu; Ruili Li; Xin Yang; Xingwei Cui; Shuo Wang; Dongdong Yu; Hongjun Li; Enqing Dong; Jie Tian
Journal:  Eur Radiol       Date:  2017-04-10       Impact factor: 5.315

3.  Geospatial mapping to identify feasible HIV prevention and treatment strategies that target specific settings.

Authors:  Paula M Frew; Chelsea S Lutz; Ighovwerha Ofotokun; Vincent C Marconi; Carlos Del Rio
Journal:  Ann Transl Med       Date:  2018-02

4.  Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study.

Authors:  P Vivithanaporn; G Heo; J Gamble; H B Krentz; A Hoke; M J Gill; C Power
Journal:  Neurology       Date:  2010-08-25       Impact factor: 9.910

5.  HIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS Project.

Authors:  N S Ku; Y Lee; J Y Ahn; J E Song; M H Kim; S B Kim; S J Jeong; K-W Hong; E Kim; S H Han; J Y Song; H J Cheong; Y G Song; W J Kim; J M Kim; D M Smith; J Y Choi
Journal:  HIV Med       Date:  2014-02-24       Impact factor: 3.180

Review 6.  Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics.

Authors:  Ankit Shah; Mohitkumar R Gangwani; Nitish S Chaudhari; Alexy Glazyrin; Hari K Bhat; Anil Kumar
Journal:  Neurotox Res       Date:  2016-06-30       Impact factor: 3.911

7.  Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection.

Authors:  Michael J Peluso; Dieter J Meyerhoff; Richard W Price; Julia Peterson; Evelyn Lee; Andrew C Young; Rudy Walter; Dietmar Fuchs; Bruce J Brew; Paola Cinque; Kevin Robertson; Lars Hagberg; Henrik Zetterberg; Magnus Gisslén; Serena Spudich
Journal:  J Infect Dis       Date:  2013-03-04       Impact factor: 5.226

8.  Improved survival in HIV-infected persons: consequences and perspectives.

Authors:  Nicolai Lohse; Ann-Brit Eg Hansen; Jan Gerstoft; Niels Obel
Journal:  J Antimicrob Chemother       Date:  2007-07-02       Impact factor: 5.790

Review 9.  Pathogenesis of HIV in the central nervous system.

Authors:  Victor Valcour; Pasiri Sithinamsuwan; Scott Letendre; Beau Ances
Journal:  Curr HIV/AIDS Rep       Date:  2011-03       Impact factor: 5.071

Review 10.  HIV and neurocognitive dysfunction.

Authors:  Serena Spudich
Journal:  Curr HIV/AIDS Rep       Date:  2013-09       Impact factor: 5.071

View more
  4 in total

1.  Principal component analysis denoising improves sensitivity of MR diffusion to detect white matter injury in neuroHIV.

Authors:  Ryan P Bell; Christina S Meade; Syam Gadde; Sheri L Towe; Shana A Hall; Nan-Kuei Chen
Journal:  J Neuroimaging       Date:  2022-01-12       Impact factor: 2.486

2.  Brain Volumetric Alterations in Preclinical HIV-Associated Neurocognitive Disorder Using Automatic Brain Quantification and Segmentation Tool.

Authors:  Ruili Li; Yu Qi; Lin Shi; Wei Wang; Aidong Zhang; Yishan Luo; Wing Kit Kung; Zengxin Jiao; Guangxue Liu; Hongjun Li; Longjiang Zhang
Journal:  Front Neurosci       Date:  2021-08-11       Impact factor: 4.677

3.  Application of Diffusion Tensor Imaging (DTI) in the Diagnosis of HIV-Associated Neurocognitive Disorder (HAND): A Meta-Analysis and a System Review.

Authors:  Juming Ma; Xue Yang; Fan Xu; Hongjun Li
Journal:  Front Neurol       Date:  2022-07-07       Impact factor: 4.086

4.  Altered gray matter structural covariance networks in drug-naïve and treated early HIV-infected individuals.

Authors:  Ruili Li; Yuxun Gao; Wei Wang; Zengxin Jiao; Bo Rao; Guangxue Liu; Hongjun Li
Journal:  Front Neurol       Date:  2022-09-20       Impact factor: 4.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.